AAPG (Ascentage Pharma Group) Forward P/E Multiple
Ascentage Pharma Group is strengthening its global authority in oncology by developing breakthrough therapies. Current revenues are based on the supply of targeted drugs to Chinese clinics, while the expansion of international trials supports operational cash flow. Comparing the company's forward P/E NTM on GURU.Markets, we see a balance of these factors, where 0.00 shows the current value of the metric, reflecting the market's pricing of all R&D costs.
Summary analytical data breakdowns for Ascentage Pharma Corp (AAPG)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Ascentage Pharma Group|AAPG - Long-Term Liabilities to Capital|Short-Term Debt to Capital Ascentage Pharma Group|AAPG - Company Aggregate Debts|Debt to Book Capitalization Ratio Ascentage Pharma Group International|AAPG - Long-Term Debt Volume|Company Short-Term Debts Ascentage Pharma|Quick Ratio ascentage.com
- financial results and valuation multiples details:
AAPG - Company Net Income|Expected Profit Ascentage Pharma Group|AAPG - Price to Earnings Multiple|Projected Price to Earnings Ascentage|AAPG - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Ascentage Pharma Group International|AAPG - Operating profit EBITDA|Net earnings per share (EPS TTM) Ascentage Pharma|AAPG - Net earnings per share for the trailing year|Quarterly EPS earnings growth ascentage.com|AAPG - Earnings per share growth rate in current year|Expected earnings per share growth for next year Ascentage Pharma Group
- sales volume and revenue indicators:
Comprehensive company analysis:AAPG Ascentage Pharma
The forward P/E reflects the ratio of the current market share price to the projected earnings per share, allowing for an assessment of the premium paid for expected earnings. Analyzing the forward P/E value of Ascentage Pharma Group helps correlate investor speculative optimism with the actual commercialization rates of the company's targeted therapies, confirming the status of this innovator in global oncology.
Main competitors
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|CGON - Projected Price to Earnings|URGN: Projected Price to Earnings|BCAX - Forward P/E Multiple|Personalis (PSNL) - Future Price to Earnings|Erasca Inc - Future Price to Earnings Multiple|DCTH (Delcath) - Forward P/E Multiple|Projected Price to Earnings Ratio Y-mAbs Corp YMAB|Forward P/E Multiple AURA|Forward P/E Multiple candeltx.com (CADL)|Future Price to Earnings Accuray ARAY|Market Cap to Projected Earnings SELLAS Life Sciences Group, Inc. (SLS)|Actuate Therapeutics, Inc - Forward P/E Multiple|Citius Oncology Inc (CTOR) - Projected Price to Earnings|HURA: Forward P/E Multiple|Projected Price to Earnings Ratio protaratx.com (TARA)|Future Price to Earnings Fate Therapeutics|Price to Future Earnings Ratio WHWK (Aadi Bio)|Projected Price to Earnings TCRX (TScan Therapeutics)|Market Cap to Future Earnings Ratio CSBR|Forward P/E Multiple XBIT (XBiotech)|Forward P/E Multiple CEL-SCI Corp. CVM|OS Therapies - Forward P/E Multiple|Forward Price to Earnings Multiple radiopharmtheranostics.com (RADX)|ARTV: Forward P/E Multiple|Projected Price to Earnings Ratio Adlai Nortye (ANL)|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings Xilio Therapeutics, Inc. (XLO)|RENB: Price to Expected Earnings Ratio|Forward P/E Multiple MURA (Mural Oncology)|Future Price to Earnings Multiple KAPA|OnKure - Forward P/E Multiple|GDTC - Forward P/E Multiple|curis.com (CRIS) - Future Price to Earnings|Apollomics - Future Price to Earnings Multiple|Future Price to Earnings Tharimmune Corp|Projected Price to Earnings Advanced Biomed Corp (ADVB)|Forward P/E Multiple GNPX|Forward P/E Multiple calidibio.com (CLDI)|Sunshine Biopharma, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple XBIO|Salarius - Forward P/E Multiple|Forward Price to Earnings Multiple Kitov Pharma (PPBT)|aoncology.com (AONC) - Future Price to Earnings|beigene.com - Future Price to Earnings Multiple|Future Price to Earnings Checkpoint Therapeutics, Inc.|Projected Price to Earnings Ratio elevationoncology.com ELEV|Projected Price to Earnings ICAD (iCAD, Inc.)|Forward P/E Multiple ikenaoncology.com (IKNA)|Future Price to Earnings Notable Labs, Ltd. NTBL|VIRX (Viracta Therapeutics Inc.) - Price to Expected Earnings Ratio|MorphoSys - Forward P/E Multiple|NAYA - Forward P/E Multiple|AAPGV: Forward P/E Multiple
